Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;39(7):742-52.
doi: 10.1016/j.ctrv.2013.02.005. Epub 2013 Apr 1.

mTOR inhibitors in advanced breast cancer: ready for prime time?

Lesley-Ann Martin  1 , Fabrice André, Mario Campone, Thomas Bachelot, Guy Jerusalem
Affiliations
Review

mTOR inhibitors in advanced breast cancer: ready for prime time?

Lesley-Ann Martin et al. Cancer Treat Rev. 2013 Nov.

Abstract

Current therapeutic approaches for advanced breast cancer frequently _target receptors mediating cell survival and proliferation, such as the estrogen receptor and/or progesterone receptor and human epidermal growth factor receptor-2. Although these approaches are effective for many patients, treatment resistance is common. Therefore, new treatment approaches are needed for patients with advanced breast cancer. Mammalian _target of rapamycin is a highly conserved serine-threonine kinase that acts as a major signaling hub that integrates and synergizes with cellular proliferation, survival, and/or motility signals mediated by estrogen receptor, human epidermal growth factor receptor-2, and other receptor tyrosine kinases. Dysregulation of mammalian _target of rapamycin signaling occurs in various tumor types, including breast cancer, and has been associated with cancer pathogenesis, disease progression, and treatment resistance. Recent clinical trials show that combined inhibition of mammalian _target of rapamycin and estrogen receptor represents an effective strategy for treating hormone receptor-positive advanced breast cancer progressing on nonsteroidal aromatase inhibitor therapy, and data from ongoing trials combining mammalian _target of rapamycin inhibition with human epidermal growth factor receptor-2-_targeted therapy are awaited. This review focuses on the molecular rationale underlying strategies to enhance sensitivity to treatment in hormone receptor-positive and human epidermal growth factor receptor-2-positive advanced breast cancer, the clinical efficacy of such approaches, and future perspectives.

Keywords: Advanced breast cancer; Endocrine resistance; Estrogen receptor; Everolimus; Exemestane; Human epidermal growth factor receptor-2; Progesterone receptor; mTOR inhibitor.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

  NODES
twitter 2